bradykinin antagonist
Recently Published Documents


TOTAL DOCUMENTS

87
(FIVE YEARS 1)

H-INDEX

26
(FIVE YEARS 1)

2020 ◽  
Vol 13 (9) ◽  
pp. 259 ◽  
Author(s):  
Bahareh Rasaeifar ◽  
Patricia Gomez-Gutierrez ◽  
Juan J. Perez

Angiotensin converting enzyme 2 (ACE2) downregulation is a key negative factor for the severity of lung edema and acute lung failure observed in patients infected with SARS-CoV-2. ACE2 downregulation affects the levels of diverse peptide mediators of the renin-agiotensin-aldestosterone and kallikrein-kinin systems, compromising vascular hemostasis. Increasing evidence suggests that the inflammatory response observed in covid-19 patients is initiated by the action of kinins on the bradykinin receptors. Accordingly, the use of bradykinin antagonists should be considered as a strategy for therapeutic intervention against covid-19 illness progression. Presently, icatibant is the only bradykinin antagonist drug approved. In the present report, we investigated the molecular features characterizing non-selective antagonists targeting the bradykinin receptors and carried out a in silico screening of approved drugs, aimed at the identification of compounds with a non-selective bradykinin antagonist profile that can be evaluated for drug repurposing. The study permitted to identify eight compounds as prospective non-selective antagonists of the bradykinin receptors, including raloxifene; sildenafil; cefepime; cefpirome; imatinib; ponatinib; abemaciclib and entrectinib.


2013 ◽  
Vol 34 (3) ◽  
pp. 467-471 ◽  
Author(s):  
Sigurdur T Sigurdsson ◽  
Olaf B Paulson ◽  
Arne Høj Nielsen ◽  
Svend Strandgaard

The lower limit of autoregulation of cerebral blood flow (CBF) can be modulated with both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB). The influence of bradykinin antagonism on ARB-induced changes was the subject of this study. CBF was measured in Sprague–Dawley rats with laser Doppler technique. The blood pressure was lowered by controlled bleeding. Six groups of rats were studied: a control group and five groups given drugs intravenously: an ACE inhibitor (enalaprilat), an ARB (candesartan), a bradykinin-2 receptor antagonist (Hoe 140), a combination of enalaprilat and Hoe 140, and a combination of candesartan and Hoe 140. In the control group, the lower limit of CBF autoregulation was 54±9 mm Hg (mean±s.d.), with enalaprilat it was 46±6, with candesartan 39±8, with Hoe 140 53±6, with enalaprilat/Hoe 140 52±6, and with candesartan/Hoe 140 50±7. Both enalaprilat and candesartan lowered the lower limit of autoregulation of CBF significantly. The bradykinin antagonist abolished not only the effect of the ACE inhibitor but surprisingly also the effect of the ARB on the lower limit of CBF autoregulation, the latter suggesting an effect on intravascular bradykinin.


FEBS Journal ◽  
2010 ◽  
Vol 277 (24) ◽  
pp. 5146-5160 ◽  
Author(s):  
Stephanie Jutras ◽  
Magdalena Bachvarova ◽  
Mamadou Keita ◽  
Jean-Loup Bascands ◽  
Anne-Marie Mes-Masson ◽  
...  

Neuropeptides ◽  
2010 ◽  
Vol 44 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Orlando L. Catanzaro ◽  
Damian Dziubecki ◽  
Pablo Obregon ◽  
Ricardo R. Rodriguez ◽  
Pierre Sirois

2006 ◽  
Vol 10 (S1) ◽  
pp. S79-S79
Author(s):  
E.J. Lim ◽  
M.A. Kim ◽  
J. Lee ◽  
S.S. Min ◽  
Y.L. Kam ◽  
...  

2006 ◽  
Vol 14 (7S_Part_20) ◽  
pp. P1088-P1089
Author(s):  
Ruiqing Ni ◽  
Diana Rita Kindler ◽  
Marie Rouault ◽  
Giovanna Diletta Ielacqua ◽  
Jan Klohs

Sign in / Sign up

Export Citation Format

Share Document